DULAGLUTIDE AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES (REWIND): A DOUBLE-BLIND, RANDOMISED PLACEBO-CONTROLLED TRIAL ArticleGerstein H.C., Dyal L., Hall S., Rao-Melacini P., Wong G., Colhoun H.M., Dagenais G.R., Diaz R., Lakshmanan M., Riesmeyer J.S., Atisso C.M., Pais P., Xavier D., Probstfield J., Riddle M.C., Rydén L., Avezum A., Basile J., Chung N., Conget I. ...Lancet. Том 394. 2019. С. 121-130
IMMUNE INFLAMMATORY RELATIONSHIP WITH HEMODYNAMIC PARAMETERS IN PATIENTS WITH ALCOHOLIC CARDIOMYOPATHY ArticleGoncharov A., Moiseev V.S., Panchenko L.F., Kiyakbaev G.K., Goncharov I.S.European Journal of Heart Failure. Том 16. 2014. С. 16-17
DYNAMICS OF INFLAMMATORY CYTOKINES IN PATIENTS WITH ALCOHOLIC CARDIOMYOPATHY ON STANDARD HEART FAILURE THERAPY ArticleGoncharov A., Moiseev V.S., Panchenko L.F., Kiyakbaev G.K., Shavarove A.A., Romanova V.A.European Journal of Heart Failure. Том 16. 2014.